| Abstract: Objective: To investigate the correlation between the dose of cytarabine and the degree of myelosuppression in consolidation therapy for acute myeloid leukemia (AML). Methods: Clinical features and laboratory investigations of 141 AML patients were retrospectively analyzed, and the screening criteria were first diagnosis of primary AML, complete morphological remission achieved by 1-2 induction chemotherapy treatments, first consolidation treatment after remission at our hospital and no relapse during treatment. According to the dose of cytarabine in the consolidation regimen, the patients were divided into high-dose cytarabine group and low-dose cytarabine group to investigate the factors affecting thrombocytopenia as well as granulocyte deficiency during consolidation therapy in AML patients. Results: High-dose cytarabine group showed a higher proportion of grade 3 or higher thrombocytopenia and agranulocytosis than low-dose cytarabine group (p < 0.01, p < 0.001), and both of them appeared earlier than low-dose cytarabine group (p < 0.001, p < 0.001). There was no significant difference between the high-dose cytarabine group and the low-dose cytarabine group in terms of the duration of grade 3 or higher thrombocytopenia and agranulocytosis. Age and peripheral platelet count before consolidation therapy were independent factors influencing the duration of grade 3 or higher thrombocytopenia and agranulocytosis in patients. Conclusion: AML consolidation therapy with cytarabine dose did not affect the duration of grade 3 or higher thrombocytopenia and agranulocytosis, and thrombocytopenia and agranulocytosis appeared earlier in the high-dose cytarabine group on consolidation therapy, which contributed to the shortening of hospitalization and thus the saving of healthcare resources. |
